

Product Development Partnerships Fund, 2018-2022

Addendum Three – 21 November 2017

Correction to the Competitive Grant Guidelines

On p 6, under section 6.1, the closing date for submission of proposals in the table has been changed from 15 December 2018 to 15 December 2017.

Questions about the Product Development Partnership Fund

Q1. Could you specify which countries overall are considered priority by DFAT for the impact section (delivery / access). In other words could you define which countries are consider priority within “the Indo-Pacific region” and whether there is a priority ranking.

A1. There is no defined list of priority countries for the Indo-Pacific for the PDP Fund and there is no priority ranking of countries.

DFAT’s priority ODA countries are listed on the DFAT website.

Q2. As a research institute, to put in a funding submission, do we have to partner with a commercial enterprise (ie a private sector company) or can we partner with another research institute?

A2. There is no requirement for applicants to partner with any specific type/s of organisations. It is up to applicants to determine what partnerships are most relevant to deliver the expected outputs.

For you information, PDPs are non-profit organizations that use public and philanthropic funds to engage the pharmaceutical industry and academic research institutions to undertake research and development (R & D) for diseases of the developing world that they would normally be unable or unwilling to pursue independently without additional incentive. Unlike large pharmaceutical companies, or academic institutions, PDPs tend not to undertake R&D, manufacturing, nor distribution in-house, but rather allocate resources to the most promising projects, provide technical insight, facilitate partner R&D and access activities and manage project portfolios to fulfil

objectives. This “virtual R&D” structure also provides additional flexibility and lowers overhead costs, which frees up capital for other investments.

For this round of funding the expected outputs from PDPs are:

Registration of a minimum number of new or modified products/regimes for patient use in the Indo-Pacific by 2022. (Actual number of products to be determined depending on specific PDP pipeline.)

Availability dimensions of access (affordability, market analysis, geographic availability, stock, partnerships for procurement and distribution) for products that are ready for market in the Indo-Pacific are addressed where relevant.

This means that any proposal would need to demonstrate how these outputs will be achieved by 2022.

Applications will be assessed using the technical selection criteria, which is included in the Competitive Grant Guidelines. Please note that the ability for PDPs to demonstrate a pipeline of relevant products is weighted at 40%.

Attachment to these addenda

Revised Product Development Partnerships Fund Competitive Grant Guidelines, 21 November 2017.